AMCR vs RXRX · P/E 18, rev $23.51B vs rev $14.1M
Amcor PLC (AMCR) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Amcor PLC (AMCR) is a packaging & containers company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported AMCR revenue for 2026-06-30 was $23.51B. Net income was $1.11B. Revenue was up 362.5% from 2025-06-30 to 2026-06-30. AMCR currently screens at market cap $22.52B and trailing P/E 17.6.
Latest reported RXRX revenue for 2026-06-30 was $14.1M. Net income was -$248.5M. RXRX currently screens at market cap $1.75B.
AMCR currently screens at market cap $22.52B and trailing P/E 17.6. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the AMCR and RXRX stock pages for the full models.
Not investment advice.